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Table S3: Model parameters 
Parameter Mean and 95%CI of generated 
distribution 
Sampling distribution and 
parameters (if not sampled, then 
blank) 
Reference/notes 
Average duration of injection until 
final cessation in years (1/µ3) 
20 (5.8-34.2) 
 
uniform (min=5, max=35) See text. Assumed longer duration than 
self-reported current average duration 
injecting, consistent with modeling 
estimates from St. Petersburg9 
Proportion of PWID who are female 
(pfemale) 
0.36 (0.31, 0.41) -Ekaterinburg 
0.25 (0.21, 0.30) - Omsk 
Beta (alpha=136, beta=244) in 
Ekaterinburg 
Beta (alpha=89, beta=261) in Omsk 
Estimated from Ekaterinburg and 
Omsk data 
Proportion of PWID in high-risk 
group (ever incarcerated) at entry to 
injecting (pprison) 
0.15 (0.11, 0.19) -Ekaterinburg 
0.10 (0.07, 0.13) - Omsk 
Beta (alpha=45, beta=255) in 
Ekaterinburg 
Beta (alpha=35, beta=315) in Omsk 
Estimated from Ekaterinburg and 
Omsk data 
Opioid overdose mortality rate per 
year (µ1) 
0.020 (0.006-0.034) uniform (min 0.005, max 0.035) Estimated 2%/year in St 
Petersburg.10,14  
Non-overdose mortality rate per 
year (µ2) 
1/50 
 
Estimated assuming injection initiation 
at 20 years and life expectancy at 7020 
Injection-related infection rate per 
year in latent phase (βinj) 
varied to fit model   
Sexual-related infection rate per 
year in latent phase (βsex) 
varied to fit model   
Seed HIV prevalences in 1996 (by 
risk and sex in Ekaterinburg and 
risk only in Omsk due to minimal 
differences by sex)  
varied to fit model   
Relative risk of injecting related HIV 
transmission if in high-risk group 
compared to low risk (RRhigh) 
varied to fit model   
Relative risk of injecting related HIV 
transmission if female compared to 
male (RRfemale) 
varied to fit model   
Rate from low risk to high risk 
group (r) 
varied to fit model   
ART recruitment rate at baseline in 
the community (αc) 
varied to fit model   
Cofactor increase in HIV 
transmission probability during: 
Initial acute phase of high viremia 
(ε) 
14.5 (3.7 – 25.5) uniform (min=3, max=26) 21,22 
Cofactor increase in HIV 
transmission probability during: 
pre-AIDS phase of high viremia (ι) 
 4 (1.2 - 6.8) uniform (min=1, max=7) 21,22 
Duration of initial period of high 
viremia in years (1/γ) 
0.24   21  
Duration of latent period of viremia 
in years (1/κ) 
8.38   21,23 
Duration of pre-AIDS period of high 
viremia in years (1/τ) 
0.75   21,23 
Duration of AIDS period in years 
(1/θ) 
0.83  21,23 
ART discontinuation rate per year 
when not on OAT (δc) 
6.5% (3%-10%) uniform (min 3%, max 10%) assumed similar to European data24,25 
Rate of leaving harm reduction 
intervention per year ( ζ ) 
0.45 (0.36 –0.54) uniform (min=0.36, max=0.54) Assumed similar average duration on 
OAT as in other lower/middle income 
settings26  
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Figure S1: Number of HIV tests and new HIV diagnoses among drug users in Omsk Oblast (Federal AIDS Center data)1 
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Figure S2. Model schematics for HIV progression and ART model components among PWID. The model is additionally 
stratified by the components in Figure S2. All stages are stratified by injecting risk (indicated by superscript i, where i=0 for low risk 
and 1 for high risk), sex (superscript j, where j=0 for males and 1 for females) and intervention status (indicated by subscript k, where 
k=0 for off and k=1 for on).  
 
	
 
  
Suscep'ble	
Acute	
Latent	
Pre-AIDS	
AIDS		
ART	
ART	
ART	
HIV-related	death	
γ	
κ	
τ	
θ	
λijinj	+	λsex			
		
α	
ψk	δ	
ψk	δ	
ψkδ	
α	
α	
νκ	
		
ντ	
		
ρθ	
Ψk	μ1		+μ2+μ3	
	
	
Ψk	μ1	+μ2+μ3	
	
	
Ψk	μ1		+μ2+μ3	
	
	
Ψk	μ1		+μ2+μ3	
	
	
Ψkμ1		+μ2+μ3	
	
	
Ψk	μ1		+μ2+μ3	
	
	
Ψk	μ1		+μ2+μ3	
	
	
Ψk	μ1		+μ2+μ3	
	
	
HIV-related	death	
On	ART	
12	
	
Figure S3. Model schematic for stratification of model based on (A) harm reduction program status and (B) risk. If recruited 
onto harm reduction with OAT, then a proportion of PWID die when transitioning on and off OAT (see text for details). 
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Figure S4. Calibration of HIV prevalence by sex in (A: males, B: females) Omsk and (C: males, D: females) Ekaterinburg. 
Observed data shown as circles (with 95% confidence intervals as whiskers). Solid line denotes median model projection, with dashed 
lines representing the 2.5%-97.5% interval.  
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Figure S5. Calibration of HIV prevalence by history of incarceration in (A: never, B: ever) Omsk and (C: never, D: ever) 
Ekaterinburg. Observed data shown as circles (with 95% confidence intervals as whiskers). Solid line denotes median model 
projection, with dashed lines representing the 2.5%-97.5% interval. 
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Figure S6. Calibration of proportion of PWID with a history of incarceration in (A) Omsk and (B) Ekaterinburg (dashed lines 
represent 95% CI). Observed data shown as circles (with 95% confidence intervals as whiskers). Solid line denotes median model 
projection, with dashed lines representing the 2.5%-97.5% interval. 
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Figure S7. Calibration of proportion of new cases attributed to sexual transmission in (A) Omsk and (B) Ekaterinburg (dashed 
lines represent 95% CI). Observed data shown as circles (with 95% confidence intervals as whiskers). Solid line denotes median 
model projection, with dashed lines representing the 2.5%-97.5% interval. 
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Figure S8. Model projections for the proportion of ART coverage among PWID in (A) Omsk and (B) Ekaterinburg in the 
following scenarios: base-case (blue), harm reduction scale-up (green), and harm reduction plus ART scale-up (orange). 
Observed data shown as circles (with 95% confidence intervals as whiskers). Solid lines denotes median model projections.	
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Figure S8.  Model projections of PWID population sizes in Omsk (A) and Ekaterinburg (B) using a population scaled to 10,000 
PWID in 1996. 
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Figure S9.  All-cause crude death rates per 100 population among PWID in Omsk (A) and Ekaterinburg (B). Solid 
lines represent median death rates and dashed lines represent 2.5 – 97.5 interval for base case rate. 
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Figure S10.  HIV-related crude death rates per 100 population among PWID in Omsk (A) and Ekaterinburg (B).  
Solid lines represent median death rates and dashed lines represent 2.5 – 97.5 interval for base case rate.  
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Figure S11.  Overdose-related crude death rates per 100 population among PWID in Omsk only. Solid lines 
represent median death rates and dashed lines represent 2.5 – 97.5 interval for base case rate. 
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Figure S12: Model projections of impact of integrated harm reduction and HIV services on HIV prevalence among 
males (A) and females (C) in Omsk and males (B) and females (D) in Ekaterinburg.  Median trajectories are shown 
and dashed lines represent 2.5-97.5 uncertainty bounds for the base case.  
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Figure S13: Model projections of impact of integrated harm reduction and HIV services on HIV prevalence among 
ever incarcerated (A) and never incarcerated (C) PWID in Omsk and ever incarcerated (B) and never incarcerated 
(D) PWID in Ekaterinburg.  Median trajectories are shown and dashed lines represent 2.5-97.5 uncertainty bounds for 
the base case. 
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